UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $64.00 price target on the stock.

URGN has been the topic of a number of other research reports. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Tuesday, February 18th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, UroGen Pharma currently has an average rating of “Buy” and a consensus price target of $40.00.

UroGen Pharma Stock Performance

Shares of URGN opened at $9.74 on Tuesday. The business has a 50-day simple moving average of $10.67 and a two-hundred day simple moving average of $12.09. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 52 week low of $9.45 and a 52 week high of $20.70. The stock has a market cap of $228.44 million, a price-to-earnings ratio of -3.09 and a beta of 1.08.

Insider Transactions at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

A number of large investors have recently made changes to their positions in the business. KLP Kapitalforvaltning AS purchased a new position in UroGen Pharma in the fourth quarter worth about $59,000. Lazard Asset Management LLC bought a new stake in shares of UroGen Pharma in the 4th quarter valued at approximately $67,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after purchasing an additional 3,856 shares during the period. BNP Paribas Financial Markets increased its position in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in UroGen Pharma during the 4th quarter valued at $101,000. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.